|Target disease||human papillomavirus|
|CAS Registry Number|
|ATC code||J07 J07|
Human papilloma virus (HPV) vaccines may prevent infections by certain types of
- Information about the cervical cancer vaccine or HPV vaccine, Cancer Council Australia.
- "HPV", MedlinePlus, NIH.
- Human Papillomavirus (HPV), .
- Human Papillomavirus (HPV) Vaccines (.
- Markowitz, L. E.; Dunne, E. F.; Saraiya, M.; Lawson, H. W.; Chesson, H.; Unger, E. R.; Centers for Disease Control Prevention (CDC); Advisory Committee on Immunization Practices (ACIP) (2007). "Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control 56 (RR-2): 1–24.
- "HPV Vaccines".
- "The Genital HPV Infection Fact Sheet".
- |Tay, S. K. (2012). "Cervical cancer in the human papillomavirus vaccination era". Current Opinion in Obstetrics and Gynecology 24 (1): 3–7.
- Kohout, T; Stewart, A. "New Report Examines Laws that Would Mandate HPV Vaccine for Young Women". Jacobs Institute for Women's Health, George Washington University. Retrieved 2010-02-13.
- Glaxo cervical cancer shot approved in Australia, .
- De Vuyst, H.; Clifford, G. M.; Nascimento, M. C.; Madeleine, M. M.; Franceschi, S. (2009). "Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis". International Journal of Cancer 124 (7): 1626–1636.
- Cortez, Michelle Fay and Pettypiece, Shannon. "Merck Cancer Shot Cuts Genital Warts, Lesions in Men" Bloomberg News. (Bloomberg.com) 13 November 2008.
- "FDA: Gardasil approved to prevent anal cancer". 2010. Retrieved January 15, 2015.
- "FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers" (press release). 2008-09-12. Retrieved 2010-02-13.
- Masters, Coco (May 11, 2007). "Oral Sex Can Add to HPV Cancer Risk".
- "FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV" (press release). 10 December 2014. Retrieved 9 January 2015.
- Medical News Today.
- Dunne, EF; Unger, ER; Sternberg, M (February 2007). "Prevalence of HPV infection among females in the United States". JAMA: the journal of the American Medical Association 297 (8): 813–19.
- American Social Health Association "Genital HPV is the most common STD in America; an estimated 80% of sexually active individuals will contract it at some point in their lives."
- "Study Reveals High Infection Rate In Teens For Virus Linked To Cervical Cancer" Science Daily "The research, reported by Darron R. Brown, M.D., and colleagues at the Indiana University School of Medicine, found four out of five sexually active adolescent females infected with the human papillomavirus."
- Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ (2006). "HPV-mediated cervical carcinogenesis: Concepts and clinical implications". J. Pathol. 208 (2): 152–64.
- Cervical Cancer Action, Funded by the Rockefeller Foundation.
- National Cancer Institute SEER fact sheet on cervical cancer accessed 30 March 2007.
- "Cervical cancer". MedlinePlus. Retrieved 15 November 2014.
- "Worldwide", NCCC Online.
- Women's Health Channel "Cervical Dysplasia: Overview, Risk Factors"
- Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. (2005). "Global Cancer Statistics, 2002". CA: A Cancer Journal for Clinicians 55 (2): 74–108.
- "Human Papillomavirus (HPV) Vaccines: Q & A". Fact Sheets: Risk Factors and Possible Causes.
- "FDA Approves New Indication for Gardasil to Prevent Genital Warts in Men and Boys" (Press release). U.S. Food and Drug Administration (FDA). Retrieved 2009-10-30.
- Centers for Disease Control and Prevention (CDC) (2010). "FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR. Morbidity and mortality weekly report 59 (20): 630–632.
- Castle PE, Scarinci I (2009). "Should HPV vaccine be given to men?". BMJ 339 (7726): 872–3.
- Rettner, Rachael. "Boys Should Get HPV Vaccine Too, CDC Says".
- "CDC panel recommends HPV vaccine for boys, too". October 26, 2011.
- Rosenthal, Elisabeth (2008-08-19). "Drug Makers' Push Leads to Cancer Vaccines' Fast Rise".
- Kim, J. J.; Goldie, S. J. (October 2009). "Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States". British Medical Journal 339 (7726): 909–19.
- "Cancer Vaccines Get a Price Cut in Poor Nations".
- "Gay men seeking HPV vaccine".
- Moi, Harald; Iversen, Ole-Erik (2011-12-17). "Gi guttene jentevaksine".
- "HPV Vaccine Update". Your Cancer Today. 2007-12-11.
- 5 November 2007, New Data Presented on GARDASIL, Merck's Cervical Cancer Vaccine, in Women Through Age 45. Retrieved through web archive on February 23, 2009
- Kresge, Kristen Jill (January 2006). "Cervical cancer vaccines".
- "New data show Cervarix, GSK'S HPV 16/18 cervical cancer candidate vaccine, is highly immunogenic and well tolerated in women over 25 years of age". GlaxoSmithKline. 2006-06-05. Archived from the original on 2007-09-27. Retrieved 2007-01-27.
- Harper DM, Franco EL, Wheeler CM (April 2006). "Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial". Lancet 367 (9518): 1247–55.
- De Vincenzo, Rosa; et al. (3 December 2014). "Long-term efficacy and safety of human papillomavirus vaccination". Int J Womens Health 6: 999–1010.
- "Committee opinion no. 467: human papillomavirus vaccination". Obstet Gynecol 116 (3): 800–3. September 2010.
- "Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model". BMJ. 7 January 2015.
- "A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women". N Engl J Med. 2015.
- Schuchat, Anne (2015). "HPV "Coverage"". N Engl J Med 2015.
- Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004-08-20). "Against which human papillomavirus types shall we vaccinate and screen? The international perspective". Int J Cancer 111 (2): 278–85.
- Wittet S. & Tsu V. (2008). "Cervical cancer prevention and the Millennium Development Goals". Bulletin of the World Health Organization 86 (6): 488–90.
- "ESGO Statement on Cervical Cancer Vaccination" (PDF). ESGO. 2007.
- "Cervarix Marketing in Kenya". Medical News Today. Retrieved 2010-09-17.
- Gardasil Researcher Speaks Out, Sharyl Attkisson, CBS News, August 19, 2009
- Yerman, M. G. (28 December 2009). "An Interview with Dr. Diane M. Harper, HPV Expert". Huffington Post. Retrieved 28 August 2013.
- "Human Papillomavirus (HPV) Vaccines".
- "HPV Vaccine Information for Clinicians—Fact Sheet". CDC.
- "Human Papillomavirus (HPV) Vaccine Recommendations" (PDF). FDA.
- Merck Pregnancy Registries—GARDASIL
- "Who Should NOT Get Vaccinated with these Vaccines?".
- "HPV Vaccine and Pregnancy". eMedTV.
- "Human papillomavirus (HPV) vaccines for Australians" (PDF). National Centre for Immunisation Research and Surveillance Factsheet. March 2013.
- Arnheim-Dahlstrom, L.; Pasternak, B.; Svanström, H.; Sparén, P.; Hviid, A. (2013). "Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort study". BMJ 347: f5906.
- "GARDASIL®, Merck's HPV Vaccine, Available to Developing Countries through UNICEF Tender". BusinessWire. May 9, 2013. Retrieved September 8, 2013.
- "Reports of Health Concerns Following HPV Vaccination". Vaccine Safety.
- "Information from FDA and CDC on Gardasil and its Safety".
- "HPV Vaccine—Questions & Answers for the Public".
- "More American Girls And Women Have HPV Than First Thought". Medical News Today. Retrieved 2008-05-28.
- New Report Examines Laws that Would Mandate HPV Vaccine for Young Women George Washington University, December 27, 2007
- Lowy DR, Schiller JT (May 2006). "Prophylactic human papillomavirus vaccines". The Journal of Clinical Investigation 116 (5): 1167–73.
- D'Souza G, Kreimer AR, Viscidi R (May 2007). "Case-control study of human papillomavirus and oropharyngeal cancer". The New England Journal of Medicine 356 (19): 1944–56.
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Walboomers, 1999, The Journal of Pathology, Wiley Online Library
- Cottler L, Garvin EC, Callahan C (September 2006). "Condom use and the risk of HPV infection". The New England Journal of Medicine 355 (13): 1388–9 ; author reply 1389.
- Winer RL, Hughes JP, Feng Q (June 2006). "Condom use and the risk of genital human papillomavirus infection in young women". The New England Journal of Medicine 354 (25): 2645–54.
- Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR (October 2004). "Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic". Sexually transmitted diseases 31 (10): 601–7.
- Avert.org STD Statistics for the USA
- Genital HPV Infection—CDC Fact Sheet
- Arteaga, Arkaitz. "The Shape and Structure of hpv". Retrieved January 15, 2015.
- "leftside". Ciitn.missouri.edu. 2007-01-22. Retrieved 2013-12-29.
- "FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus". U.S. Food and Drug Administration. 2006-06-08. Retrieved 2009-11-13.
- McNeil C (April 2006). "Who invented the VLP cervical cancer vaccines?". J. Natl. Cancer Inst. 98 (7): 433.
- U.S. Patent 7,476,389, titled "Papilloma Virus Vaccines", was granted to co-inventors Ian Frazer and Jian Zhou (Zhou posthumously) on January 13, 2009. Its U.S. application was filed on January 19, 1994 but claimed priority under a July 20, 1992 PTC filing to the date of an initial [AU] Australian patent application filed on July 19, 1991.
- Merck Reports Double-Digit Earnings-Per-Share Growth for Second Quarter 2007
- "Glaxo prepares to launch Cervarix after EU okay". Reuters. 2007-09-24. Retrieved 2008-07-18.
- "October 16, 2009 Approval Letter—Cervarix". U.S. Food and Drug Administration (FDA). October 16, 2009. Retrieved 2009-11-13.
- Cutts FT, Franceschi S, Goldie S (2007). "Human papillomavirus and HPV vaccines: a review". Bull World Health Organ 85 (9): 719–26.
- Professor Ian Frazercreator of the HPV vaccine. "Human papillomavirus vaccine - New and underused vaccines support - Types of support". GAVI Alliance. Retrieved 2013-12-29.
- Tabrizi S. Brotherton J. Kaldor J et al. Fall in Human Papillomavirus Prevalence Following a National Vaccination Program. Journal of Infectious Diseases. October 24, 2012.
- Immuinise Australia: Information about the HPV immunisation program
- Immunise Australia HPV.
- 2011 Annual Surveillance Report of HIV, viral hepatitis, STIs. (page 28)
- Pharmaceutical Benefits Scheme Recommendations.
- Minister Plibersek announces HPV vaccination for boys.
- National Advisory Committee on Immunization. (2012). Update On Human Papillomavirus Vaccines. In Public Health Agency of Canada (Ed.), Canada Communicable Disease Report (Vol. 37, pp. 1-62)
- Canadian Immunization Committee. Recommendations for human papillomavirus immunization programs. Canada Communicable Disease Report. 2014;40(8). Public Health Agency of Canada. Publicly Funded Immunization Programs in Canada. 2014; http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php - fn_2, Bonanni P, Bechini A, Donato R, et al. Human papilloma virus vaccination: impact and recommendations across the world. Therapeutic Advances in Vaccines. 2014.
- Public Health Agency of Canada. Publicly Funded Immunization Programs in Canada. 2014; http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php - fn_2.
- Human Papillomavirus (HPV) Prevention and HPV Vaccine: Questions and Answers
- HPV Immunization Launched
- "McGuinty Government Launches Life-Saving HPV Immunization Program:".
- "HPV Immunization Launched".
- "British Columbia To Launch Program To Provide HPV Vaccine to Sixth-Grade Girls Next Fall if Approved, Official Says". Kaiser Daily Women's Health Policy (
- Carvajal (4 September 2012). "Girón ya está vacunando contra el papiloma humano". Vanguardia (in Spanish). Retrieved 29 July 2015.
- "Vacuna contra el Papiloma Humano será gratuita". Caracol Radio (Actualidad) (Prisa Radio). 3 May 2013. Retrieved 29 July 2015.
- "ABC VPH vaccine". www.minsalud.gov.co. Retrieved 29 July 2015.
- "HPV vaccination: Coverage". National Institute for Health Data and Disease Control. 18 February 2010. Retrieved 10 August 2013.
- "Cancer of the cervix: reimbursement of Gardasil" (in French). 17 July 2007. Retrieved 10 August 2013.
- Fagbire, O. J. (26 March 2007). "Gardasil, Merck HPV Vaccine, Gets German And Italian Approval For Girls". Vaccine Rx. Archived from the original on 28 September 2007. Retrieved 10 August 2013.
- Karakitsos, P. (7 March 2008). "Vaccination against HPV in Greece" (in Greek). Retrieved 10 August 2013.
- "The vaccine against cervical cancer and Cervarix vs Gardasil" (in Greek). 12 February 2008. Retrieved 10 August 2013.
- "Information om det allmänna barnvaccinationsprogrammet" (in Swedish). Smittskyddsinstitutet. Retrieved 10 August 2013.
- Siegel, Judy. "Health Ministry decides to offer free HPV vaccine to 13-year-old girls | JPost | Israel News". JPost. Retrieved 2013-12-29.
- Gilmour, S.; Kanda, M.; Kusumi, E.; Tanimoto, T.; Kami, M.; Shibuya, K. (2013). "HPV vaccination programme in Japan". The Lancet 382 (9894): 768.
- "New technologies for cervical cancer prevention: from scientific evidence to program planning.". Pan American Health Organization. Retrieved 2012-04-18.
- "Progress Toward Implementation of Human Papillomavirus Vaccination—the Americas, 2006–2010". Center for Disease and Control Prevention. Retrieved 2012-04-18.
- Having the HPV vaccine is your choice and this website contains information to help you decide | Cervical Cancer Vaccine
- Green, A. (7 June 2013). "Life saving cancer vaccine will be difficult to implement". Mail & Guardian. Retrieved 7 August 2013.
- Botha, M. H.; Dochez, C. (2012). "Introducing human papillomavirus vaccines into the health system in South Africa". Vaccine (Elsevier Ltd) 30 (Suppl 3): C28–34.
- SAPA (15 May 2013). "Schoolgirls to get cancer vaccine". ioL News. Retrieved 7 August 2013.
- "가다실 제품 허가 공지". 2007-06-27. Retrieved 2007-08-06.
- Roberts, Michelle (2007-02-23). "Gay men seek 'female cancer' jab". BBC.
- "NHS Cervical Screening Program". Retrieved 2008-06-26.
- "1 in 4 US teen girls got cervical cancer shot".
- "More US Girls Now Getting Cervical Cancer Vaccine". Discovery and Development (Rockaway,
- "HPV Vaccine Information For Young Women".
- Niccolai, LM; Hansen, CE (1 July 2015). "Practice- and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage: A Systematic Review.". JAMA pediatrics 169 (7): 686–92.
- Caskey, R; Lindau, ST; Alexander, GC (November 2009). "Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey". The Journal of Adolescent Health 45 (5): 453–62.
- Stobbe, M (June 19, 2013). "Study: Vaccine against sexually transmitted HPV cut infections in teen girls by half". Star Tribune. Retrieved August 7, 2013.
- Knox, R (June 19, 2013). "Vaccine Against HPV Has Cut Infections In Teenage Girls". NPR. Retrieved June 21, 2013.
- Schwartz (October 2010). "HPV Vaccination's Second Act: Promotion, Competition, and Compulsion". American Journal of Public Health 100 (10): 1841–4.
- "Vaccines for Children Program (VFC)". Centers for Disease Control and Prevention. Retrieved 10 August 2013.
- "ACA Preventative Services Benefits for Women and Pregnant Women". Immunization for Women. Retrieved 10 August 2013.
- HPV Vaccine, NCSL.
- MIRIAM JORDAN (2008-10-01). "Gardasil Requirement for Immigrants Stirs Backlash". The Wall Street Journal. Retrieved 2009-01-15.
- "Green card seekers won't have to get HPV vaccine". 2009-11-16. Retrieved 2011-01-31.
- HPV Vaccine—Why Your Doctor Doesn't Offer the HPV Vaccine—Gardasil
- Examines Cost of HPV Vaccine Gardasil"Detroit News". Kaiser Family Foundation. March 29, 2007.
- A question of protection
- New York Times In Republican Race, a Heated Battle Over the HPV Vaccine
- Sprigg, Peter (2006-07-15). "Pro-Family, Pro-Vaccine—But Keep It Voluntary".
- Coyne, Brendan (2005-11-02). "Cervical Cancer Vaccine Raises 'Promiscuity' Controversy".
- IF07B01, Family Research Council, February 7, 2008.
- Position Statement: Human Papillomavirus Vaccines, Focus on the Family.
- "HPV Vaccination Does Not Lead to Increased Sexual Activity" (press release). AAP. Retrieved 3 February 2014.
- "Lifesaving Politics", Ms. Magazine, Spring 2007: 12–13.
- Artega, Arkaitz. "The Shape and Structure of HPV". Zimbio. Retrieved 7 March 2012.
- "New HPV Vaccine Under Study". Medical College of Georgia, ScienceDaily. 2007-11-20. Retrieved 2008-03-01.
- Ma, B.; Roden, R.; Wu, T. C. (2010). "Current status of human papillomavirus vaccines". Journal of the Formosan Medical Association = Taiwan yi zhi 109 (7): 481–483.
- Jagu, S.; Karanam, B.; Gambhira, R.; Chivukula, S. V.; Chaganti, R. J.; Lowy, D. R.; Schiller, J. T.; Roden, R. B. S. (2009). "Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines". JNCI Journal of the National Cancer Institute 101 (11): 782–792.
- Van Driel, W. J.; Ressing, M. E.; Brandt, R. M.; Toes, R. E.; Fleuren, G. J.; Trimbos, J. B.; Kast, W. M.; Melief, C. J. (1996). "The current status of therapeutic HPV vaccine". Annals of medicine 28 (6): 471–477.
- Roden RB, Ling M, Wu TC (August 2004). "Vaccination to prevent and treat cervical cancer". Human pathology 35 (8): 971–82.
- Albarran y Carvajal, A.; De La Garza, A.; Cruz Quiroz, B. J.; Vazquez Zea, E.; d??Az Estrada, I.; Mendez Fuentez, E.; l??Pez Contreras, M.; Andrade-Manzano, A.; Padilla, S.; Varela, A. R.; Rosales, R. (2007). "MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: A phase I/II study". BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 21 (1): 47–59.
- Corona Gutierrez, C. M.; Tinoco, A.; Navarro, T.; Contreras, M. L. P.; Cortes, R. R.; Calzado, P.; Reyes, L.; Posternak, R.; Morosoli, G.; Verde, M. L.; Rosales, R. (2004). "Therapeutic Vaccination with MVA E2 Can Eliminate Precancerous Lesions (CIN 1, CIN 2, and CIN 3) Associated with Infection by Oncogenic Human Papillomavirus". Human Gene Therapy 15 (5): 421–431.
- Albarran y Carvajal, A.; De La Garza, A.; Cruz Quiroz, B. J. C.; Vazquez Zea, E.; Díaz Estrada, I.; Mendez Fuentez, E.; López Contreras, M.; Andrade-Manzano, A.; Padilla, S.; Varela, A. R. ?R.; Rosales, R. (2007). "MVA E2 Recombinant Vaccine in the Treatment of Human Papillomavirus Infection in Men Presenting Intraurethral Flat Condyloma". BioDrugs 21 (1): 47–59.
- "Virolab, Inc. - FORM 8-K/A - June 24, 2011". Getfilings.com. Retrieved 2013-12-29.
- "Virolab". Virolabintl.com. Retrieved 2013-12-29.
There is a working therapeutic HPV vaccine that has been clinically tried in Mexico. Developed by Ricardo Rosales. It has gone through 3 clinical trials and has been approved for use by the Mexican government. It is a MVA based vaccine with an e2 bovine protein added in. It has been shown to completely eliminate HPV to the point that patients test negative for the presence of HPV in blood tests. The vaccine is officially called the MEL-1 vaccine but also known as the MVA-E2 vaccine. The vaccine has proven to be safe as far as is known there have been no side effects or other documented issues. The vaccine is administered locally to the infected areas and also given in the arm if the infection is mild.
In addition to preventive vaccines, such as Gardasil and Cervarix, laboratory research and several human clinical trials are focused on the development of therapeutic HPV vaccines. In general these vaccines focus on the main HPV oncogenes, E6 and E7. Since expression of E6 and E7 is required for promoting the growth of cervical cancer cells (and cells within warts), it is hoped that immune responses against the two oncogenes might eradicate established tumors.
There is also substantial research interest in the development of therapeutic vaccines, which seek to elicit immune responses against established HPV infections and HPV-induced cancers.
There are high-risk HPV types, that are not affected by available vaccines. Ongoing research is focused on the development of HPV vaccines that will offer protection against a broader range of HPV types. One such method is a vaccine based on the minor capsid protein L2, which is highly conserved across HPV genotypes. Efforts for this have included boosting the immunogenicity of L2 by linking together short amino acid sequences of L2 from different oncogenic HPV types or by displaying L2 peptides on a more immunogenic carrier.
Many organizations such as the American Academy of Pediatrics disagree with the argument that the vaccine increases sexual activity among teens. Dr. Christine Peterson, director of the University of Virginia's Gynecology Clinic, said "The presence of seat belts in cars doesn't cause people to drive less safely. The presence of a vaccine in a person's body doesn't cause them to engage in risk-taking behavior they would not otherwise engage in."
Conservative groups in the U.S. have publicly opposed the concept of making HPV vaccination mandatory for pre-adolescent girls, asserting that making the vaccine mandatory is a violation of parental rights. They also say that it will lead to early sexual activity, giving a false sense of immunity to sexually transmitted disease. (See Peltzman effect) Both the Family Research Council and the group Focus on the Family support widespread (universal) availability of HPV vaccines but oppose mandatory HPV vaccinations for entry to public school.
Religious right and conservative groups
The vaccine manufacturers also offer help for people who cannot afford HPV vaccination. GSK has the Vaccines Access Program, which provides Cervarix free of charge to women who do not have insurance and who have a low income, and who are ages 19 to 25 and therefore too old for the Medicaid Vaccines for Children Program. For example, Merck offers the Merck Vaccine Patient Assistance Program, which provides Gardasil for free to people over the age of 19 who do not have health insurance or cannot afford to pay for the vaccine.
However, Medicaid covers HPV vaccination in accordance with the ACIP recommendations, and immunizations are a mandatory service under Medicaid for eligible individuals under age 21.  In addition, Medicaid includes the Vaccines for Children Program.  This program provides immunization services for children 18 and under who are Medicaid eligible, uninsured, underinsured, receiving immunizations through a Federally Qualified Health Center or Rural Health Clinic, or are Native American or Alaska Native.
There has been significant opposition from health insurance companies to covering the cost of the vaccine ($360).
Health insurance companies
Opposition in the United States
Between July 2008 and December 2009, proof of the first of three doses of HPV Gardasil vaccine was required for women ages 11–26 intending to legally enter the United States. This requirement stirred controversy because of the cost of the vaccine, and because all the other vaccines so required prevent diseases which are spread by respiratory route and considered highly contagious. The Centers for Disease Control and Prevention repealed all HPV vaccination directives for immigrants effective December 14, 2009.
Source: National Conference of State Legislatures
|Alabama||HB 42 would allow parents the option of immunizing female students entering the sixth grade, and requires the Department of Health and Senior Services to directly mail age appropriate information to parents or guardians to those students regarding the connection between HPV and cervical cancer and the availability of the immunization.||Passed|
|Alaska||Voluntary vaccination program||Passed|
|Florida||SB 1116 Would require the Department of Health to adopt a rule adding HPV/cervical cancer to the list of communicable diseases for which immunizations are recommended; requires that schools provide the parents or guardians of certain public school students information regarding the disease and the availability of a vaccine; requires the department to prescribe the required information.||Not passed|
|Georgia||HB 736 Would require public Schools to provide parents or guardians of sixth grade female students information concerning the infection and the immunization against the human papillomavirus.|
|Hawaii||HCR 71 Would request the Department of Health to make human papillomavirus immunization available to indigent patients and through the teen VAX program, and urging insurers to offer coverage for human papillomavirus immunization to female policyholders eleven to twenty-six years of age.||Not Passed|
|Iowa||SSB 3097 Would create a study bill for a HPV public awareness program and make appropriations for the public awareness program, provision of vaccinations, and cervical cancer screenings.||In committee|
|Kansas||HR 6019 Resolution would urge the FDA to use caution in approving new vaccines such as Gardasil which has had a number of health problems including some deaths associated with the use of this vaccine.||In committee|
|Kentucky||HR 80 Would urge females ages 9 to 26 and males ages 11 to 26 to obtain the Human papillomavirus (HPV) vaccination and all citizens to become more knowledgeable about the benefits of HPV vaccination.||Passed|
|Maryland||HB 411 Would require the Statewide Advisory Commission on Immunizations to study the safety of the human papillomavirus (HPV) vaccine; requires the Commission to include specified components in the study, make recommendations, and report the results of its study.||Passed|
|Minnesota||HF 1758 Would require the commissioner of health to prepare informational materials on vaccines including the HPV vaccines and encourages public and private schools with students in grades 6-12 to provide this information to parents in a cost-effective and programmatically effective manner. (Introduced 3/16/09)|
|Michigan||SB 1062 and SB 1063 Each would require health insurers to provide coverage for humpan papillomavirus screenings for cervical cancer.||In committee|
|Mississippi||HB 1512 Would require health benefit plans to cover HPV screenings.||Not Passed|
|Missouri||HB 1935 Would require health insurers to provide coverage for human papillomavirus screenings for cervical cancer.||In committee|
S 1163 Would require health insurers and State Health Benefits Program and SEHBP to provide coverage for screening for cervical cancer, including testing for HPV. (Sent to Committee 1/23/12)
A 2185 Would require insurers and State health care coverage programs to cover cost of HPV vaccine.
SB 98 (same as AB 2360) Would encourage voluntary, informed vaccination against human papillomavirus (HPV). (Amended in Senate Committee on Health 1/5/12)
AB 699 Would require immunization against HPV for children born after Jan. 1, 1996. (Sent to Assembly Committee on Health 1/5/11) AB 1946 Would require insurance companies to provide coverage for the vaccine against human papilloma virus. (Sent to committee 1/12/11) AB 2360 Would encourage voluntary, informed vaccination against human papillomavirus (HPV) for school-aged children and their parents or guardians. (Sent to committee 1/18/11) SB 4708 Would require insurance companies to cover HPV vaccine.
|Oregon||HB 2794 Would require health benefit plans to provide coverage of human papillomavirus vaccine for female beneficiaries who are 11 years of age or older.||Passed|
|Pennsylvania||HB 524 Would require health insurance policies to provide coverage for vaccinations for human papilloma virus.||In committee|
|South Carolina||HB 4497 Would enact the Cervical Cancer Prevention Act and allow the Department of Health and Environmental Control to offer the option of an HPV vaccine series to female students entering the seventh grade at the request of their parent or guardian pending state and federal funding.||In committee|
|Texas||HB 2220 Would allow the Executive Commissioner of the Health and Human Services Commission to require immunization against human papillomavirus or other immunizations for a person's admission to elementary or secondary school.||In committee|
HB 1419 Would repeal the HPV vaccination requirement for female children. (Passed House 1/21/11, Indefinitely passed by the Senate Committee 2/17/11)
HB 65 Would repeal the requirement for children to receive the HPV vaccination for school attendance. (Left in committee 2/14/12) HB 824 Would require that the Commonwealth shall assume liability for any injury resulting from administration of the human papillomavirus vaccine. HB 1112 Would eliminate the requirement for vaccination against human papillomavirus for female children.
|Passed House and sent to Senate|
Other states are also preparing bills to handle issuing the HPV Vaccine.
The National Conference of State Legislatures periodically issues summaries of HPV vaccine related legislation.
Almost all pieces of legislation currently pending in the states that would make the vaccine mandatory for school entrance have an "opt-out" policy.
Other measures that have been considered include requiring insurers to cover HPV vaccination, and funding HPV vaccines for those without insurance. The cost of the HPV vaccines for females under 18 who are uninsured is covered under the federal Vaccines for Children Program. As of 23 September 2010, vaccines are required to be covered by insurers under the Patient Protection and Affordable Care Act. HPV vaccines specifically are to be covered at no charge for women, including those who are pregnant or nursing.
Shortly after the first HPV vaccine was approved, bills to include the vaccine among those that are mandatory for school attendance were introduced in many states. Only two such bills passed (in Virginia and Washington DC) during the first four years after vaccine introduction. Mandates have been effective at increasing uptake of other vaccines, such as mumps, measles, rubella, and hepatitis B (which is also sexually transmitted). However most such efforts developed for five or more years after vaccine release, while financing and supply were arranged, further safety data was gathered, and education efforts increased understanding, before mandates were considered.
Since the approval of Gardasil in 2006 and despite low vaccine uptake, prevalence of HPV among teenagers aged 14–19 has been cut in half with an 88% reduction among vaccinated women. No decline in prevalence was observed in other age groups, indicating the vaccine to have been responsible for the sharp decline in cases. The drop in number of infections is expected to in turn lead to a decline in cervical and other HPV-related cancers in the future.
A survey was conducted in 2009 to gather information about knowledge and adoption of the HPV vaccine. Thirty percent of 13- to 17-year-olds and 9% of 18- to 26-year-olds out of the total 1,011 young women surveyed reported receipt of at least one HPV injection. Knowledge about HPV varied; however, 5% or fewer subjects believed that the HPV vaccine precluded the need for regular cervical cancer screening or safe-sex practices. Few girls and young women overestimate the protection provided by the vaccine. Despite moderate uptake, many females at risk of acquiring HPV have not yet received the vaccine.
According to the US Centers for Disease Control and Prevention (CDC), getting as many girls vaccinated as early and as quickly as possible will reduce the cases of cervical cancer among middle-aged women in 30 to 40 years and reduce the transmission of this highly communicable infection. Barriers include the limited understanding by many people that HPV causes cervical cancer, the difficulty of getting pre-teens and teens into the doctor's office to get a shot, and the high cost of the vaccine ($120/dose, $360 total for the three required doses, plus the cost of doctor visits). Community based interventions can increase the uptake of HPV vaccination among adolescents.
As of late 2007, about one quarter of US females age 13–17 years had received at least one of the three HPV shots. By 2014, the proportion of such females receiving a vaccination had risen to 38%. The government began recommending vaccination for boys in 2011; by 2014, the vaccination rate among boys (at least one dose) had reached 35%.
It will be many years before the vaccination programme has an effect upon cervical cancer incidence so women are advised to continue accepting their invitations for cervical screening.
In September 2012, Gardasil replaced Cervarix as the HPV vaccination of choice due to its added protection against genital warts.
By the end of the catch up campaign, all girls under 18 will have been offered the HPV vaccine.
- girls aged between 16 and 18 from autumn 2009, and
- girls aged between 15 and 17 from autumn 2010.
HPV vaccination with Cervarix was introduced into the national immunisation programme in September 2008, for girls aged 12–13 across the UK. A two-year catch up campaign started in Autumn 2009 to vaccinate all girls up to 18 years of age. Catch up vaccination will be offered to:
In the UK the vaccine is licensed for girls aged 9 to 15, for women aged 16 to 26, and for boys aged 9–15.
Introduced in 2013. Target Group 9–26. Fully financed by national health authorities. Administration in schools currently suspended owing to objections and concerns raised by the Catholic Board, but fully available in local health centers.
Trinidad and Tobago
On July 27, 2007, South Korean government approved Gardasil for use in girls and women aged 9 to 26 and boys aged 9 to 15. Approval for use in boys was based on safety and immunogenicity but not efficacy.
Cervical cancer represents the most common cause of cancer-related deaths—more than 3,000 deaths per year—among women in South Africa because of high HIV prevalence, making introduction of the vaccine highly desirable. A Papanicolaou test program was established in 2000 to help screen for cervical cancer, but since this program has not been implemented widely, vaccination would offer more efficient form of prevention. In May 2013 the Minister of Health of South Africa, Aaron Motsoaledi, announced the government would provide free HPV vaccines for girls aged 9 and 10 in the poorest 80% of schools starting in February 2014 and the fifth quintile later on. South Africa will be the first African country with an immunisation schedule that includes vaccines to protect people from HPV infection, but because the effectiveness of the vaccines in women who later become infected with HIV is not yet fully understood, it is difficult to assess how cost-effective the vaccine will be. Negotiations are currently underway for more affordable HPV vaccines since they are up to 10 times more expensive than others already included in the immunisation schedule.
The vaccine was added to the national immunization program in 2008, to target girls in the population aged 10. The vaccine is being administer by clinics and schools.
The publicly funded New Zealand HPV Immunisation Programme began on 1 September 2008. Gardasil is available free for New Zealand girls and young women born on or after 1 January 1990 through general practices, some family planning clinics and participating schools. HPV immunization is part of the regular immunization schedule for girls in year 8 at school (or age 12 if not delivered through a school-based programme). There is also a catch-up programme for older girls. Girls born in 1990 and 1991 have until 31 December 2011 to start the programme for free. Girls born from 1992 onwards have until their 20th birthday to start the programme for free. Over 82,000 New Zealand girls and young women have chosen to get the HPV immunisation in the programme's first year.
The vaccine was introduced in 2008 to 5% of the population. This percentage of the population had the lowest development index which correlates with the highest incidence of cervical cancer. The HPV vaccine is delivered to girls 12 – 16 years old following the 0-2-6 dosing schedule. By 2009 Mexico had expanded the vaccine use to girls, 9–12 years of age, the dose schedule in this group was different, the time elapsed between the first and second dose was six months and the third dose 60 months later. In 2011 Mexico approved a nationwide use of HPV vaccination program to include vaccination of all 9-year-old girls.
In 2013 
Both Cervarix and Gardasil are approved for use within Kenya by the Pharmacy and Poisons Board. However, at a cost of 20,000 Kenyan shillings, which is more than the average annual income for a family, the director of health promotion in the Ministry of Health, Nicholas Muraguri, states that many Kenyans are unable to afford the vaccine.
Introduced in 2010, widely available only since April 2013. Fully financed by national health authorities. In June 2013, however, Japan's Vaccine Adverse Reactions Review Committee (VARRC) suspended recommendation of the vaccine due to fears of adverse events. This directive has been criticized by researchers at the University of Tokyo as a failure of governance since the decision was taken without presentation of adequate scientific evidence.
Introduced in 2012. Target age group 13–14. Fully financed by national health authorities only for this age group. For the year 2013–2014, girls in the eighth grade may get the vaccine free of charge only in school, and not in Ministry of Health offices or clinics. Girls in the ninth grade may receive the vaccine free of charge only at Ministry of Health offices, and not in schools or clinics. Religious and conservative groups are expected to refuse the vaccination.
|Country||Date of introduction||Gender(s)||Target age group||Financed by||Policy|
|Austria||2006||M/F||9–15||Fully financed by patient|
|Belgium||2007||10–13||Financed 75% by national health authorities|
|Denmark||1 January 2009||F||12||Fully financed by national health authorities||Part of the Danish Childhood Vaccination program|
|France||11 July 2007||F||14–23||Financed 65% by national health authorities||Voluntary immunization for women not yet sexually active|
|Germany||26 March 2007|
|Greece||12 February 2007||F||12–26||Fully financed by national health authorities||Mandatory for all girls entering 7th grade|
|Hungary||2014||F||12||Fully financed by national health authorities. In addition subsidised by local councils for 13-14 year olds.|
|Iceland||2011||12||Fully financed by national health authorities|
|Ireland||2008||12–13||Fully financed by national health authorities|
|Italy||26 March 2007||F||12|
|Latvia||2009||12||Fully financed by national health authorities|
|Luxembourg||2008||12||Fully financed by national health authorities|
|Macedonia||2009||F||12||Fully financed by national health authorities||Mandatory; part of the national immunization schedule|
|Netherlands||2009||F||12–13||Fully financed by national health authorities|
|Norway||2009||F||12–13||Part of the national immunization program|
|Portugal||2007||13||Fully financed by national health authorities|
|Slovenia||2009||11–12||Fully financed by national health authorities|
|Spain||2007||11–14||Fully financed by national health authorities|
|Sweden||1 January 2010||F||10–12|
|Switzerland||2008||11–14||Fully financed by national health authorities|
|Fully financed by national health authorities for girls only|
The vaccine was introduced in 2012, approved for 9 aged girls. The HPV vaccine begins to delivered to girls aged 9 and older and are attending fourth grade of school. Since 2013 the age of coverage was extended to girls in school from grade four who have reached the age of 9 to grade 11th independent of age; and no schooling from age 9-17 years 11 months and 29 days old.
Canada has approved use of Gardasil. Initiating and funding free vaccination programs has been left to individual Province/Territory Governments. In the provinces of Ontario, Prince Edward Island, Newfoundland and Labrador, and Nova Scotia, free vaccinations to protect women against HPV were slated to begin in September 2007 and will be offered to girls ages 11–14. Similar vaccination programs are being planned in British Columbia and Quebec.
Two provinces have implemented HPV immunization programs for boys, Prince Edward Island and Alberta.
Currently, all Canadian provinces and territories funded HPV school-based immunization programs for females.
In July 2006, human papillomavirus vaccine against 4 types of HPV was authorized in Canada for females 9 to 26 years. In February 2010, use in males 9 to 26 years of age for prevention of genital warts was authorized.
Further information is available on the HPV Vaccination Program website at www.australia.gov.au/hpv
- males and females aged 12–13 years (ongoing program); and
- males aged between 14–15 years—until the end of the school year in 2014 (catch up program).
From February 2013, free HPV vaccine is being provided through school-based programs for:
On 12 July 2012, the Australian Government announced funding to extend the National HPV Vaccination Program to include males, with implementation commencing in all states and territories in February 2013.
In November 2011, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended the extension of the National HPV Vaccination Program to include males. The PBAC made its recommendation on the preventative health benefits that can be achieved, such as a reduction in the incidence of anal and penile cancers and other HPV-related disease. In addition to the direct benefit to males, it was estimated that routine HPV vaccination of adolescent males would contribute to the reduction of vaccine HPV-type infection and associated disease in women through herd immunity.
In October 2010, the Australian regulatory agency, the Therapeutic Goods Administration, extended the registration of the quadrivalent vaccine (Gardasil) to include use in males aged 9 through 26 years of age, for the prevention of external genital lesions and infection with HPV types 6, 11, 16 and 18.
Since the National HPV Vaccination Program commenced in 2007, there has been a reduction in HPV-related infections in young women. A study published in The Journal of Infectious Disease in October 2012 found the prevalence of vaccine preventable HPV types (6, 11, 16 and 18) in Papanicolaou test results of women aged 18–24 years has significantly decreased from 28.7% to 6.7% four years after the introduction of the National HPV Vaccination Program. A 2011 report published found the diagnosis of genital warts (caused by HPV types 6 and 11) had also decreased in young women and men.
During 2007–2009, an estimated 83% of females aged 12–17 years received at least one dose of HPV vaccine and 70% completed the 3-dose HPV vaccination course. Latest HPV coverage data on the Immunise Australia website show that by 15 years of age, over 70% of Australian females have received all three doses. This has remained steady since 2009.
The National HPV Vaccination Program for females was made up of two components: an ongoing school-based program for 12–13-year-old girls; and a time-limited catch-up program (females aged 14–26 years) delivered through schools, general practices and community immunisation services, which ceased on 31 December 2009.
In April 2007, Australia became the first country to introduce a government funded National Human Papillomavirus (HPV) Vaccination Program to protect young women against HPV infections that can lead to cancers and disease. The National HPV Vaccination Program is listed on the National Immunisation Program (NIP) Schedule and funded under the Immunise Australia Program. The Immunise Australia Program is a joint Australian, State and Territory Government initiative to increase immunisation rates for vaccine preventable diseases.
With support from the 
In developed countries, the widespread use of cervical "Pap smear" screening programs has reduced the incidence of invasive cervical cancer by 50% or more. Current preventive vaccines reduce, but do not eliminate the chance of getting cervical cancer. Therefore, experts recommend that women combine the benefits of both programs by seeking regular Pap smear screening, even after vaccination. The European Centre for Disease Prevention and Control (ECDC) has recommended all European teenage girls to be vaccinated; however Bulgaria, Cyprus, Czech Republic, Estonia, Finland, Lithuania, Poland, Slovakia and Turkey currently do not have a vaccination programme in place.
His observation of HPV oncogenic potential in human malignancy provided impetus within the research community to characterize the natural history of HPV infection, and to develop a better understanding of mechanisms of HPV-induced carcinogenesis.
Harald zur Hausen pursued his idea of HPV for over 10 years by searching for different HPV types.  This research was difficult due to the fact that only parts of the viral DNA were integrated into the host genome. He found novel HPV-DNA in cervix cancer biopsies, and thus discovered the new, tumourigenic HPV16 type in 1983. In 1984, he cloned HPV16 and 18 from patients with cervical cancer. The HPV types 16 and 18 were consistently found in about 70% of cervical cancer biopsies throughout the world.
zur Hausen went against current dogma and postulated that oncogenic human papilloma virus (HPV) caused cervical cancer. He realized that HPV-DNA could exist in a non-productive state in the tumours, and should be detectable by specific searches for viral DNA. He and others, notably workers at the Pasteur Institute, found HPV to be a heterogeneous family of viruses. Only some HPV types cause cancer.
Harald zur Hausen, a German researcher who initially suspected and later helped to prove that genital HPV infection can lead to cervical cancer, was awarded half of the $1.4 million Nobel Prize in Medicine for his work. Verification that cervical cancer is caused by an infectious agent led several other groups (see above) to develop vaccines against HPV strains that cause most cases of cervical cancer. The other half of the award went to Françoise Barré-Sinoussi and Luc Montagnier, two French virologists, for their part in the discovery of HIV.
In work that was initiated in the mid-1980s, the vaccine was developed, in parallel, by researchers at University of Rochester, the University of Queensland in Australia, and the U.S. National Cancer Institute. Researchers Ian Frazer and Jian Zhou at the University of Queensland have been accorded priority under U.S. patent law for the invention of the HPV vaccine's basis, the VLPs. In 2006, the FDA approved the first preventive HPV vaccine, marketed by Merck & Co. under the trade name Gardasil. According to a Merck press release, in the second quarter of 2007, it had been approved in 80 countries, many under fast-track or expedited review. Early in 2007, GlaxoSmithKline filed for approval in the United States for a similar preventive HPV vaccine, known as Cervarix. In June 2007 this vaccine was licenced in Australia, and it was approved in the European Union in September 2007. Cervarix was approved for use in the U.S. in October 2009.
While the study period was not long enough for cervical cancer to develop, the prevention of these cervical precancerous lesions (or dysplasias) is believed highly likely to result in the prevention of those cancers.
Gardasil and Cervarix are designed to elicit virus-neutralizing antibody responses that prevent initial infection with the HPV types represented in the vaccine. The vaccines have been shown to offer 100 percent protection against the development of cervical pre-cancers and genital warts caused by the HPV types in the vaccine, with few or no side effects. The protective effects of the vaccine are expected to last a minimum of 4.5 years after the initial vaccination.
The HPV vaccines are based on hollow virus-like particles (VLPs) assembled from recombinant HPV coat proteins. The virus possesses circular double stranded DNA and a viral shell that is composed of 72 capsomeres. Every subunit of the virus is composed of two proteins molecules, L1 and L2. The reason why this virus has the capability to affect the skin and the mucous layers is due to its structure. The primary structures expressed in these areas are E1 and E2, these proteins are responsible for the replication of the virus. E1 is a highly conserved protein in the virus, E1 is in charge of the production of viral copies is also involved in every step of replication process. The second component of this process is E2 ensures that non-specific interaction occur while interacting with E1. As a result of these proteins working together is assures that numerous amounts of copies are made within the host cell. The structure of the virus is critical because this influence the infection affinity of the virus. Knowing the structure of the virus allowed for the development of an efficient vaccine, such as Gardasil and Cervarix. The vaccines target the two high-risk HPVs, types 16 and 18 that cause the most cervical cancers. Gardasil's proteins are synthesized by the yeast Saccharomyces cerevisiae. Its protein makeup allows it to target four types of HPV. Gardasil contains inactive L1 proteins from four different HPV strains: 6, 11, 16, and 18. Each vaccine dose contains 225 µg of aluminum, 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 µg of polysorbate 80, 35 µg of sodium borate, and water. The combination of ingredients totals 0.5 mL. Together, these two HPV types currently cause about 70 percent of all cervical cancer. Gardasil also targets HPV types 6 and 11, which together currently cause about 90 percent of all cases of genital warts.
Mechanism of action
No data is kept by the U.S. government on genital wart incidence rates. It is estimated that in the U.S., at any one time about 1% of adults who have had sex have genital warts. It is estimated that about 20 million people are presently infected with HPV, and there are about six million new cases of HPV every year in the United States.
Condoms protect against HPV, but do not completely prevent transmission. College freshmen women who used condoms consistently had a 37.8% per patient-year incidence of genital HPV, compared to an incidence of 89.3% among those who did not.
There are 19 "high-risk" HPV types that can lead to the development of cervical cancer or other genital/anal cancers; some forms of HPV, particularly type 16, have been found to be associated with a form of throat cancer. Studies have found that human papillomavirus (HPV) infection is responsible for virtually all cases of cervical cancer.
About 11,000 American women are diagnosed with cervical cancer every year, and about 4,000 die per year of the disease. Most cancers occur in those who have not had Pap smears within the previous five years.
Only a small percentage of women with high-risk HPV develop cervical cancer. However, each year between 250,000 and 1 million American women are diagnosed with cervical dysplasia, which is caused by HPV and is a precursor to cervical cancer. Cervical dysplasia is painful and costly to treat.
At a given time, the overall prevalence of high-risk (cancer causing) HPV types was 15% of female participants; the prevalence of the types covered by the vaccine were 1.5% (HPV-16) and 0.8% (HPV-18). The overall prevalence of low-risk (wart causing) types was 18%, the two types covered by the vaccine were found in 1.3% (HPV-6) and 0.1% (HPV-11) of the population. Overall, the types prevented by the vaccine were found in 3.4% of female participants.
According to the Centers for Disease Control and Prevention, by the age of 50 more than 80% of American women will have contracted at least one strain of genital HPV. Both men and women can be carriers of HPV. HPV is the most common sexually transmitted infection in the US. A large percentage of the American population is infected with genital HPV because HPV is highly communicable. As a result, American public health experts recommend widespread HPV vaccination.
Prevalence of genital HPV
According to the Centers for Disease Control and Prevention (CDC) and the FDA, the rate of adverse side effects related to Gardasil immunization in the safety review was consistent with what has been seen in the safety studies carried out before the vaccine was approved and were similar to those seen with other vaccines. However, a higher proportion of syncope (fainting) were seen with Gardasil than are usually seen with other vaccines. The FDA and CDC have reminded health care providers that, to prevent falls and injuries, all vaccine recipients should remain seated or lying down and be closely observed for 15 minutes after vaccination.
As of 8 September 2013 the CDC continues to recommend Gardasil vaccination for the prevention of four types of HPV. Merck, the manufacturer of Gardasil, has committed to ongoing research assessing the vaccine's safety.
As of 1 September 2009, there have been 44 U.S. reports of death in females after receiving the vaccine. None of the 27 confirmed deaths of women and girls who had taken the vaccine were linked to the vaccine. There is no evidence suggesting that Gardasil causes or raises the risk of Guillain-Barré Syndrome. Additionally, there have been rare reports of blood clots forming in the heart, lungs and legs.
Gardasil is a 3-dose (injection) vaccine. As of 8 September 2013 there have been more than 57 million doses distributed in the United States, though it is unknown how many have been administered. There have been 22,000 Vaccine Adverse Event Reporting System (VAERS) reports following the vaccination. Ninety-two percent were reports of events considered to be non-serious (e.g., fainting, pain and swelling at the injection site (arm), headache, nausea and fever), and 9 percent were considered to be serious (death, permanent disability, life-threatening illness and hospitalization). There is no proven causal link between the vaccine and serious adverse effects; VAERS reports include any effects whether coincidental or causal. The CDC states: "When evaluating data from VAERS, it is important to note that for any reported event, no cause-and-effect relationship has been established. VAERS receives reports on all potential associations between vaccines and adverse events."
A cohort study of approximately 1 million girls found no evidence supporting associations between exposure to quadrivalent human papillomavirus vaccine and autoimmune, neurological, and venous thromboembolic adverse events.
HPV vaccines are approved for use in over 100 countries, with more than 100 million doses distributed worldwide. Extensive clinical trial and post-marketing safety surveillance data indicate that both Gardasil and Cervarix are well tolerated and safe.
The FDA has classified the HPV vaccine as a pregnancy Category B, meaning there is no apparent harm on the fetus in animal studies. HPV vaccines have not been causally related with adverse pregnancy outcomes or adverse effects on the fetus. However, data on vaccination during pregnancy is very limited and vaccination during the pregnancy term should be delayed until more information is available. If a woman is found to be pregnant during the three dose series of vaccination, the series will be postponed until pregnancy has been completed. While there is no indication for intervention for vaccine dosages administered during pregnancy, patients and health-care providers are encouraged to report exposure to vaccines to the appropriate HPV vaccine pregnancy registry.
In the Gardasil clinical trials, 1,115 pregnant women received the HPV vaccine. Overall, the proportions of pregnancies with an adverse outcome were comparable in subjects who received Gardasil and subjects who received placebo. However, the clinical trials had a relatively small sample size. Currently the vaccine is not recommended for pregnant women. The long-term effects of the vaccine on fertility are not known, but no effects are anticipated.
- People with moderate or severe acute illnesses. This does not completely exclude patients from vaccination, but postpones the time of vaccination until the illness has improved.
- People with history of immediate hypersensitivity to vaccine components. Patients with a hypersensitivity to yeast should not receive Gardasil since yeast is used in its production.
While the use of HPV vaccines can help reduce cervical cancer deaths by two thirds around the world, not everyone is eligible for vaccination. There are some factors that exclude people from receiving HPV vaccines. These factors include:
In more developed countries, populations that do not receive adequate medical care, such as poor or minorities in the United States or parts of Europe also have less access to cervical screening and appropriate treatment, and are similarly more likely to benefit. Comments made by Dr. Diane Harper, a researcher for the HPV vaccines, were interpreted as indicating that in countries where Pap smear screening is common, it will take vaccination of a large proportion of women in order to further reduce cervical cancer rates. She has also encouraged women to continue pap screening after they are vaccinated and to be aware of potential adverse effects.
Only 41% of women with cervical cancer in the developing world get medical treatment. Therefore, prevention of HPV by vaccination may be a more effective way of lowering the disease burden in developing countries than cervical screening. The European Society of Gynecological Oncology sees the developing world as most likely to benefit from HPV vaccination. However, individuals in many resource-limited nations, Kenya for example, are unable to afford the vaccine.
Current preventive vaccines protect against the two HPV types (16 and 18) that cause about 70% of cervical cancers worldwide. Because of the distribution of HPV types associated with cervical cancer, the vaccines are likely to be most effective in Asia, Europe and North America. Some other high risk types cause a larger percentage of cancers in other parts of the world. Vaccines that protect against more of the types common in cancers would prevent more cancers, and be less subject to regional variation. For instance, a vaccine against the seven types most common in cervical cancers (16, 18, 45, 31, 33, 52, 58) would prevent an estimated 87% of cervical cancers worldwide.
The National Cancer Institute states "Widespread vaccination has the potential to reduce cervical cancer deaths around the world by as much as two-thirds, if all women were to take the vaccine and if protection turns out to be long-term. In addition, the vaccines can reduce the need for medical care, biopsies, and invasive procedures associated with the follow-up from abnormal Pap tests, thus helping to reduce health care costs and anxieties related to abnormal Pap tests and follow-up procedures."
A study with 9vHPV, a 9-valent HPV vaccine that protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, came to the result that the rate of high-grade cervical, vulvar, or vaginal disease was the same as when using a quadrivalent HPV vaccine. A lack of a difference may have been caused by the study design of including women 16 to 26 years of age, who may largely already have been infected with the five additional HPV types that are additionally covered by the 9-valent vaccine.
Two doses of the vaccine may work as well as three doses.
HPV types 16, 18 and 45 contribute to 94% of cervical adenocarcinoma (cancers originating in the glandular cells of the cervix). While most cervical cancer arises in the squamous cells, adenocarcinomas make up a sizable minority of cancers. Further, Pap smears are not as effective at detecting adenocarcinomas, so where Pap screening programs are in place, a larger proportion of the remaining cancers are adenocarcinomas. Trials suggest that HPV vaccines may also reduce the incidence of adenocarcinoma.
A recent analysis of data from a clinical trial of Cervarix found that this vaccine is just as effective at protecting women against persistent HPV 16 and 18 infection in the anus as it is at protecting them from these infections in the cervix. Overall, about 30 percent of cervical cancers will not be prevented by these vaccines. Also, in the case of Gardasil, 10 percent of genital warts will not be prevented by the vaccine. Neither vaccine prevents other sexually transmitted diseases, nor do they treat existing HPV infection or cervical cancer.
Gardasil also protects against low-risk HPV types 6 and 11, which are much less likely to cause cancer, but do cause genital warts.
Both Gardasil and Cervarix have been shown to prevent cervical dysplasia from the high-risk HPV types 16 and 18 and some protection against a few closely related high-risk HPV types. However, there are other high-risk HPV types that are not affected by the vaccines. The protection against HPV 16 and 18 has lasted at least 8 years after vaccination for Gardasil and more than 9 years for Cervarix. It is thought that booster vaccines will not be necessary.
In November 2007, Merck presented new data on Gardasil. In an investigational study, Gardasil reduced incidence of HPV types 6, 11, 16 and 18-related persistent infection and disease in women through age 45. The study evaluated women who had not contracted at least one of the HPV types targeted by the vaccine by the end of the three-dose vaccination series. Merck planned to submit this data before the end of 2007 to the FDA, and to seek an indication for Gardasil for women through age 45.
When Gardasil was first introduced, it was recommended as a prevention for cervical cancer for women that were 25 years old or younger. New evidence suggests that all HPV vaccines are effective in preventing cervical cancer for women up to 45 years of age.
Harald zur Hausen's support for vaccinating boys (so that they will be protected and thereby women) was joined by professors Harald Moi and Ole-Erik Iversen in 2011.
Gardasil is in particular demand among MSMs, who are at higher risk for genital warts, penile cancer, and anal cancer.
As with females, the vaccine should be administered before infection with the HPV types covered by the vaccine occurs. Vaccination before adolescence therefore makes it more likely that the recipient has not been exposed to HPV.
From a public health point of view, vaccinating men as well as women decreases the virus pool within the population, but is only cost-effective if the uptake in the female population is extremely low. In the United States, the cost per quality-adjusted life year is greater than $100,000 for vaccinating the male population, compared to the less than $50,000 for vaccinating the female population. This assumes a 75% vaccination rate. In early 2013 the two companies who sell the most common vaccines announced a price cut to less than $5 per dose to poor countries, as opposed to $130 per dose in the US.
In males, Gardasil may reduce their risk of genital warts and precancerous lesions caused by HPV. This reduction in precancerous lesions might be predicted to reduce the rates of penile and anal cancer in men. Since penile and anal cancers are much less common than cervical cancer, HPV vaccination of young men is likely to be much less cost-effective than for young women.
On October 25, 2011, an advisory panel for the Centers for Disease Control and Prevention (CDC) voted to recommend that the vaccine be given to boys ages 11–12. The panel's recommendation is intended to prevent genital warts and anal cancers in males, and possibly prevent head and neck cancer (though the vaccine's effectiveness against head and neck cancers has not yet been proven). The Committee also made the vaccination recommendation for males 13 to 21 years who have not been vaccinated previously or who have not completed the three-dose series.
Gardasil has been shown to also be effective in preventing genital warts in males. On 9 September 2009, an advisory panel recommended that the FDA licence Gardasil in the United States for boys and men ages 9–26 for the prevention of genital warts. Soon after that, the vaccine was approved by the FDA for use in males aged 9 to 26 for prevention of genital warts and anal cancer.
HPV vaccines are approved for males in several countries, including Canada, Australia, South Korea, the United Kingdom, and the United States.
Gardasil and Cervarix are preventive vaccines and do not treat HPV infection or cervical cancer. They are recommended for women who are 9 to 25 years old who have not been exposed to HPV. However, since it is unlikely that a woman will have already contracted all four viruses, and because HPV is primarily sexually transmitted, the U.S. Centers for Disease Control and Prevention has recommended vaccination for women up to 26 years of age.
Medical uses 1
- Males 1.1
- Older women 1.2
- Efficacy 1.3
- Public health 1.4
Side effects 2
- Pregnancy 2.1
- Safety 2.2
Prevalence of genital HPV 3
- United States 3.1
- Mechanism of action 4
- History 5
Vaccine implementation 6
- Africa 6.1
- Australia 6.2
- Canada 6.3
- Colombia 6.4
- Europe 6.5
- Israel 6.6
- Japan 6.7
- Kenya 6.8
- Laos 6.9
- Mexico 6.10
- New Zealand 6.11
- Panama 6.12
- South Africa 6.13
- South Korea 6.14
- Trinidad and Tobago 6.15
- United Kingdom 6.16
United States 6.17
- Opt-out policies 184.108.40.206
- State-by-State 220.127.116.11
- Immigrants 18.104.22.168
Opposition in the United States 6.17.2
- Health insurance companies 22.214.171.124
- Religious right and conservative groups 126.96.36.199
- Legislation 6.17.1
- Therapeutic vaccines 7.1
- References 8
- External links 9
Since the vaccine only covers some high-risk types of HPV, experts still recommend that women get Pap smear screenings even after vaccination. In the US, the recommendation is for women to receive routine Pap smears beginning at age 21. Additional vaccine candidate research is occurring for next generation products to extend protection against additional HPV types.
Worldwide, HPV is the most common sexually transmitted infection in adults. For example, more than 80% of American women will have contracted at least one strain of HPV by age fifty. Although most women infected with genital HPV will not have complications from the virus, worldwide there are an estimated 529,000 new cases of cervical cancer and 275,000 deaths per year. About 85 percent of cancers, and 80% of deaths from cervical cancer occur in developing countries. In the United States, most of the approximately 11,000 cervical cancers found annually occur in women who have never had a Pap smear, or did not follow up on abnormal Pap smear results. HPV is also the cause of cervical intraepithelial neoplasia (CIN). CIN is a precursor to cervical cancer, and is painful and costly to treat. It is not known how many women worldwide are diagnosed with CIN.
Two vaccines have market approval in many countries as of 2014 (called Gardasil and Cervarix in the US). Both vaccines protect against the two HPV types (HPV-16 and HPV-18) that cause 70% of cervical cancers, 80% of anal cancers, 60% of vaginal cancers, and 40% of vulvar cancers. These HPV types also cause most HPV induced oral cancers, and some other rare genital cancers. Gardasil also protects against the two HPV types (HPV-6 and HPV-11) that cause 90% of genital warts. Both vaccines have been shown to prevent precancerous lesions of the cervix. Gardasil has been shown to prevent precursors to anal, vulvar, vaginal, and penile cancers. HPV vaccines are expected to protect against HPV induced cancers of these areas as well as HPV induced oral cancers. In December 2014, the United States' Food and Drug Administration (FDA) approved a vaccine called Gardasil 9 to protect females between the ages of 9 and 26 and males between the ages of 9 and 15 against nine strains of HPV. Gardasil 9 protects against infection with the strains covered by the first generation of Gardasil (HPV-6, HPV-11, HPV-16, and HPV-18) and protects against five other HPV strains responsible for 20% of cervical cancers (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).
and genital warts, and possibly other HPV associated cancers. anal cancer HPV vaccination is also effective in males to protect their partners from HPV infections, as well as themselves from  as well as public health officials in Australia, Canada, Europe, and the United States recommend vaccination of young women against HPV.